Fourth Annual Chicago Supportive Oncology Conference

Community Oncology

Volume 1, Number 3 (September/October 2004)

Letter from the Editor

135

 

From ivory tower to next-door neighbor: cancer centers, community physicians, access to cancer care

Lee S. Schwartzberg, MD, FACP, Editor-in-Chief

The West Clinic, Memphis, TN

When academic centers open satellite offices in your town, where does that leave community-based oncologists? Local doctors offer continuity of care; cancer centers offer specialized expertise. So can we all just get along? General oncologists need to embrace the experience of their colleagues from academia, and academics need to build bridges to the community and use their clout to help provide cancer care to those without access.

full text 70 kb

Community Translations

138

 

Predicting the outcome of breast cancer treatment by gene profiling

Summary by Matt Stenger, MS; reviewed by Lee S. Schwartzberg, MD, FACP, The West Clinic, Memphis, TN

Correlating pretreatment gene expression with clinical outcome is proving efficacious in breast tumors. The techniques are broadening the possibilities for rational treatment of breast cancer patients.

full text 77 kb

142

 

Chemotherapy for androgen-independent prostate cancer

Steven Tucker, MD, Compassionate Oncology Medical Group, Cedars-Sinai Medical Center, and Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA

Aside from fighting androgen-independent prostate cancer, physicians need to combat the nihilism that has grown up around treatment of men with this disease. Based on two large randomized clinical trials, docetaxel-based chemotherapy every 3 weeks represents a new—more hopeful—standard of care.

full text 98 kb

Original Research

149

 

Radiosurgical treatment of brain metastases in a community oncologic practice

Vladimir Ioffe, MD, Michael Miller, DO, Ajay Sandhu, MD, Geoffrey A. Neuner, BA, Shankar Giri, MD, Joseph Koen, MD, John Partington, MD, Ping Wong, PhD, and Thomas Goffman, MD

Department of Radiation Oncology and Biophysics, Eastern Virginia Medical School, and Neurosurgical Specialists, Inc., Norfolk, VA

A common complication in cancer patients, brain metastases often result in diminished functional independence. The authors retrospectively analyzed all patients treated with stereotactic radiosurgery (SRS) and whole-brain radiation therapy (WBRT) in their large community-based practice. The goal: to determine whether SRS and WBRT administered in the community can garner results comparable with those achieved at regional centers of specialization.

abstract full text 215 kb

Controversies in Patient Management

159

 

Cancer-related anemia: when dollars and cents—not science—dictate treatment

Sanjay Sethi, MD, and Howard Ozer, MD, PhD

University of Oklahoma Health Sciences Center, Oklahoma City, OK

In an increasingly cost-conscious clinical environment, practitioners may be reluctant to prescribe erythropoietic therapy for patients with mild anemia, unless reimbursement guidelines change. Erythropoietic agents are the mainstay of anemia therapy. But insurance requirements often result in delayed treatment, which is clearly unacceptable, especially given the patchwork of regulations in various states.

abstract full text 128 kb

Economics/Practice Management

166

 

Discover the genius within your organization: the benefits of personality assessment tools

Tina Carey

Tina Carey and Associates, Inc., San Gabriel, CA

Accelerated partial breast irradiation is increasingly being used as an alternative to whole breast irradiation after lumpectomy in patients with early-stage breast cancers. But is it more cost-effective?

abstract full text 85 kb

Community Dialogue

171

 

Satellite clinics: friend or foe?

Community Oncology interviews Philip Schulman, MD, chief medical oncologist of Memorial Sloan-Kettering Cancer Center at Suffolk

full text 84 kb

174

 

Sizing up the competition

Community Oncology interviews Michael S. Buchholtz, MD, FACP, a community oncologist practicing in Huntington, NY

When a major cancer center opens a satellite clinic in community oncologists’ backyard, it’s often a source of concern for local physicians. Are they encroaching on the turf of local doctors? Can they peacefully coexist with private practices? Are patients better off? To hear both sides of the story, we sat down with two physicians on Long Island on opposite sides of the divide.

full text 105 kb

Psychosocial Oncology

179

 

End of treatment—laugh or cry?

Susan E. Carter, PhD, MFT

Psycho-Oncology Specialist, Claremont, CA

Compared with the close monitoring and almost daily contact with physicians and staff, the end of chemotherapy and radiation feels, to many patients, as though they are being “dropped off a cliff.” They may be glad to finish these procedures, but the end of treatment represents a new era of doubt and worry. How to help your patients cope.

abstract full text 73 kb

Meetings Highlights & Calendar

183

 

EPEC-O: training oncologists in palliative care

full text 84 kb

184

 

Overcoming the barrier of poor health literacy

full text 45 kb

185

 

Community physicians encouraged to consider high-priority phase III trials

full text 54 kb

187

 

Meetings Calendar

full text 35 kb

Washington Update

189

 

NCI extends clinical trials to community oncologists

Brian Vastag

full text 47 kb

190

 

FDA reorganizes cancer review office

full text 40 kb

191

 

CMS releases Medicare drug reimbursement estimates for 2005

full text 62 kb

Reader Services

133

 

Guide for Authors

full text 62 kb

© 2004 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.